Comparison of Extended-Release Buprenorphine Doses for Treating High-Risk Opioid Use: A Randomized Clinical Trial.

ABSTRACT:

Importance

Patients with high-risk opioid use may require higher buprenorphine doses to maximize abstinence and retention in treatment.

Objective

To compare the efficacy and safety of 100-mg vs 300-mg once-monthly maintenance doses of extended-release buprenorphine among individuals with high-risk opioid use, including fentanyl.

Design, setting, and participants

This multicenter, randomized, double-blind clinical trial was conducted from October 26, 2021, to June 26, 2024, at 28 outpatient treatment centers in the US and Canada among treatment-seeking participants with moderate or severe opioid use disorder who injected opioids, used high doses of opioids, or used fentanyl.

Interventions

After completing buprenorphine induction and extended-release buprenorphin

SUBMITTER: Shiwach R 

PROVIDER: S-EPMC12712736 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature